{
  "facts": [
    {
      "id": "HIV-PREP-ELIG-001",
      "ta": "HIV",
      "topic": "PrEP Eligibility",
      "text": "PrEP is recommended for individuals at substantial risk of HIV acquisition, including those with sexual partners of unknown HIV status, inconsistent condom use, or recent STI diagnoses.",
      "cites": [
        "CDC PrEP Guidelines 2024"
      ]
    },
    {
      "id": "HIV-PREP-TAF-002",
      "ta": "HIV",
      "topic": "Descovy for PrEP",
      "text": "Descovy (emtricitabine/tenofovir alafenamide) is indicated for HIV PrEP in at-risk adults and adolescents weighing ≥35 kg, excluding individuals assigned female at birth at risk from receptive vaginal sex.",
      "cites": [
        "FDA Label - Descovy PrEP",
        "DISCOVER Trial"
      ]
    },
    {
      "id": "HIV-PREP-SAFETY-003",
      "ta": "HIV",
      "topic": "Renal Safety Monitoring",
      "text": "Assess renal function (eGFR, CrCl) and urinalysis before PrEP initiation and monitor every 3-6 months during treatment. Consider dose adjustment or discontinuation if eGFR <50 mL/min.",
      "cites": [
        "FDA Label - Descovy",
        "CDC PrEP Guidelines 2024"
      ]
    },
    {
      "id": "HIV-PREP-APRETUDE-004",
      "ta": "HIV",
      "topic": "Apretude (CAB-LA)",
      "text": "Apretude (cabotegravir long-acting injectable) is indicated for PrEP in at-risk adults and adolescents weighing ≥35 kg, administered as 600 mg IM every 2 months after oral lead-in or initial injections.",
      "cites": [
        "FDA Label - Apretude",
        "HPTN 083, HPTN 084 Trials"
      ]
    },
    {
      "id": "HIV-TREAT-BIKTARVY-005",
      "ta": "HIV",
      "topic": "Biktarvy for Treatment",
      "text": "Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) is a complete once-daily single-tablet regimen for treatment-naïve or virologically suppressed adults, demonstrating high barrier to resistance and favorable safety profile.",
      "cites": [
        "FDA Label - Biktarvy",
        "Study 1489, Study 1490"
      ]
    },
    {
      "id": "HIV-TREAT-CAB-006",
      "ta": "HIV",
      "topic": "Cabenuva Long-Acting",
      "text": "Cabenuva (cabotegravir/rilpivirine long-acting) is a complete monthly or every-2-month injectable regimen for virologically suppressed adults with no current or prior resistance to either component, requiring adherence and injection site management.",
      "cites": [
        "FDA Label - Cabenuva",
        "ATLAS, FLAIR Trials"
      ]
    },
    {
      "id": "HIV-TREAT-RESISTANCE-007",
      "ta": "HIV",
      "topic": "Resistance Testing",
      "text": "Genotypic resistance testing is recommended before initiating or modifying ART to guide regimen selection, particularly for integrase strand transfer inhibitor (INSTI) resistance mutations.",
      "cites": [
        "DHHS Guidelines 2024",
        "IAS-USA Recommendations"
      ]
    },
    {
      "id": "HIV-ADHERENCE-008",
      "ta": "HIV",
      "topic": "Adherence and Viral Suppression",
      "text": "Sustained viral suppression (HIV RNA <50 copies/mL) requires >95% adherence to ART. Long-acting regimens may improve adherence for patients facing daily pill burden challenges.",
      "cites": [
        "DHHS Guidelines 2024",
        "Clinical Adherence Studies"
      ]
    },
    {
      "id": "HIV-PREP-LAB-009",
      "ta": "HIV",
      "topic": "PrEP Laboratory Monitoring",
      "text": "Before PrEP initiation, confirm negative HIV test, assess HBV status, and perform STI screening. Repeat HIV testing every 3 months and STI screening every 6-12 months during PrEP use.",
      "cites": [
        "CDC PrEP Guidelines 2024",
        "USPSTF Recommendations"
      ]
    },
    {
      "id": "HIV-PREP-ADHERENCE-010",
      "ta": "HIV",
      "topic": "PrEP Adherence Strategies",
      "text": "Daily oral PrEP requires 4-7 doses per week for protective efficacy. Event-driven (on-demand) dosing may be appropriate for cisgender men who have sex with men with predictable sexual activity.",
      "cites": [
        "IPERGAY Study",
        "CDC PrEP Guidelines 2024"
      ]
    },
    {
      "id": "ONC-IO-CHECKPOINT-001",
      "ta": "Oncology",
      "topic": "Immune Checkpoint Inhibitors",
      "text": "Immune checkpoint inhibitors (anti-PD-1, anti-PD-L1, anti-CTLA-4) enhance T-cell mediated anti-tumor immunity and have transformed treatment across multiple solid tumor types, with efficacy often correlating with PD-L1 expression and tumor mutational burden.",
      "cites": [
        "NCCN Guidelines - Multiple Tumor Types",
        "FDA Labels"
      ]
    },
    {
      "id": "ONC-IO-TOXICITY-002",
      "ta": "Oncology",
      "topic": "Immune-Related Adverse Events",
      "text": "Immune-related adverse events (irAEs) can affect any organ system, most commonly skin, GI, endocrine, and hepatic. Early recognition and corticosteroid management are critical; severe (Grade 3-4) irAEs require treatment interruption and specialist consultation.",
      "cites": [
        "ASCO irAE Management Guidelines",
        "NCCN IO Toxicity Management"
      ]
    },
    {
      "id": "ONC-ADC-MECHANISMS-003",
      "ta": "Oncology",
      "topic": "Antibody-Drug Conjugates",
      "text": "Antibody-drug conjugates (ADCs) combine targeted monoclonal antibodies with cytotoxic payloads, delivering chemotherapy selectively to tumor cells expressing specific antigens (e.g., HER2, Trop-2, NECTIN-4).",
      "cites": [
        "FDA Labels - ADCs",
        "NCCN Guidelines"
      ]
    },
    {
      "id": "ONC-ADC-TOXICITY-004",
      "ta": "Oncology",
      "topic": "ADC Adverse Event Management",
      "text": "ADC-associated toxicities include neutropenia, peripheral neuropathy, ocular toxicity, and interstitial lung disease (ILD). Prophylactic growth factor support, dose modifications, and ophthalmologic monitoring may be required.",
      "cites": [
        "FDA Labels - ADCs",
        "Clinical Practice Guidelines"
      ]
    },
    {
      "id": "ONC-BIOMARKER-PD-L1-005",
      "ta": "Oncology",
      "topic": "PD-L1 Testing",
      "text": "PD-L1 immunohistochemistry (IHC) expression levels guide patient selection for certain IO therapies. Tumor Proportion Score (TPS) ≥50% or Combined Positive Score (CPS) thresholds vary by indication and agent.",
      "cites": [
        "NCCN NSCLC Guidelines",
        "FDA Companion Diagnostic Approvals"
      ]
    },
    {
      "id": "ONC-BIOMARKER-TMB-006",
      "ta": "Oncology",
      "topic": "Tumor Mutational Burden",
      "text": "Tumor mutational burden (TMB-High, ≥10 mutations/megabase) is an FDA-approved biomarker for pembrolizumab monotherapy in advanced solid tumors after prior treatment, indicating potential for enhanced IO response.",
      "cites": [
        "FDA Label - Pembrolizumab",
        "KEYNOTE-158 Trial"
      ]
    },
    {
      "id": "ONC-ORAL-ONCOLYTIC-007",
      "ta": "Oncology",
      "topic": "Oral Oncolytic Adherence",
      "text": "Oral oncolytics require patient education on dosing schedules, drug-drug interactions, food effects, and toxicity self-monitoring. Specialty pharmacy support and early refill coordination reduce treatment interruptions.",
      "cites": [
        "ASCO/ONS Oral Chemotherapy Standards",
        "NCCN Patient Education"
      ]
    },
    {
      "id": "ONC-ORAL-TOXICITY-008",
      "ta": "Oncology",
      "topic": "Oral TKI Toxicity Management",
      "text": "Tyrosine kinase inhibitors (TKIs) commonly cause diarrhea, rash, hypertension, and hand-foot syndrome. Dose modifications and supportive care (antidiarrheals, topical steroids, antihypertensives) maintain treatment continuity.",
      "cites": [
        "NCCN Guidelines - Supportive Care",
        "FDA Labels"
      ]
    },
    {
      "id": "ONC-PATHWAY-INTEGRATION-009",
      "ta": "Oncology",
      "topic": "Clinical Pathway Integration",
      "text": "Evidence-based clinical pathways standardize treatment selection per NCCN categories of evidence and preference, optimizing outcomes while managing cost and toxicity. Pathway adherence requires EHR integration and multidisciplinary tumor board alignment.",
      "cites": [
        "ASCO Quality Oncology Practice Initiative",
        "NCCN Clinical Pathways"
      ]
    },
    {
      "id": "ONC-SURVIVORSHIP-010",
      "ta": "Oncology",
      "topic": "Survivorship Care Planning",
      "text": "Survivorship care plans document treatment history, potential late effects, surveillance schedules, and transition to primary care. Addressing long-term toxicities (neuropathy, cardiotoxicity, secondary malignancies) is essential.",
      "cites": [
        "ASCO Survivorship Guidelines",
        "NCCN Survivorship Guidelines"
      ]
    },
    {
      "id": "CV-GDMT-HFREF-001",
      "ta": "Cardiovascular",
      "topic": "HFrEF Guideline-Directed Medical Therapy",
      "text": "Guideline-directed medical therapy (GDMT) for HFrEF includes four pillars: ACE-I/ARB/ARNI, beta-blockers, MRAs, and SGLT2 inhibitors, each providing mortality and hospitalization benefits with additive effects.",
      "cites": [
        "ACC/AHA Heart Failure Guidelines 2022",
        "ESC HF Guidelines 2021"
      ]
    },
    {
      "id": "CV-ARNI-ENTRESTO-002",
      "ta": "Cardiovascular",
      "topic": "Sacubitril/Valsartan (Entresto)",
      "text": "Sacubitril/valsartan (ARNI) is superior to enalapril in reducing cardiovascular death and HF hospitalization in HFrEF patients (NYHA Class II-IV, EF ≤40%). Requires 36-hour ACE-I washout to avoid angioedema.",
      "cites": [
        "PARADIGM-HF Trial",
        "FDA Label - Entresto"
      ]
    },
    {
      "id": "CV-SGLT2-HF-003",
      "ta": "Cardiovascular",
      "topic": "SGLT2 Inhibitors in Heart Failure",
      "text": "SGLT2 inhibitors (dapagliflozin, empagliflozin) reduce HF hospitalization and cardiovascular death in HFrEF and HFpEF, independent of diabetes status. Benefits include diuresis, improved renal outcomes, and metabolic effects.",
      "cites": [
        "DAPA-HF Trial",
        "EMPEROR-Reduced",
        "ACC/AHA Guidelines"
      ]
    },
    {
      "id": "CV-SGLT2-CKD-004",
      "ta": "Cardiovascular",
      "topic": "SGLT2i in Chronic Kidney Disease",
      "text": "SGLT2 inhibitors slow CKD progression (eGFR decline, ESKD, CV/renal death) in patients with and without diabetes, including CKD Stage 3-4 (eGFR ≥20 mL/min). Initiation safe despite transient eGFR dip.",
      "cites": [
        "DAPA-CKD Trial",
        "EMPA-KIDNEY",
        "KDIGO 2022 Guidelines"
      ]
    },
    {
      "id": "CV-SGLT2-SAFETY-005",
      "ta": "Cardiovascular",
      "topic": "SGLT2i Safety and Sick Day Rules",
      "text": "SGLT2 inhibitors carry risks of euglycemic DKA (rare), genital mycotic infections, and volume depletion. Educate patients on sick day rules: withhold during acute illness, dehydration, or fasting to prevent DKA.",
      "cites": [
        "FDA Safety Communications",
        "Endocrine Society Clinical Practice Guidelines"
      ]
    },
    {
      "id": "CV-MRA-SPIRONOLACTONE-006",
      "ta": "Cardiovascular",
      "topic": "Mineralocorticoid Receptor Antagonists",
      "text": "Spironolactone and eplerenone reduce mortality in HFrEF (NYHA Class II-IV) when added to ACE-I and beta-blockers. Monitor potassium and renal function; avoid if K+ >5.0 mEq/L or CrCl <30 mL/min.",
      "cites": [
        "RALES Trial",
        "EMPHASIS-HF",
        "ACC/AHA Guidelines"
      ]
    },
    {
      "id": "CV-BETA-BLOCKER-007",
      "ta": "Cardiovascular",
      "topic": "Beta-Blockers in HFrEF",
      "text": "Evidence-based beta-blockers (carvedilol, metoprolol succinate, bisoprolol) reduce mortality and hospitalization in stable HFrEF. Initiate at low dose and titrate to target or maximum tolerated dose over weeks.",
      "cites": [
        "MERIT-HF Trial",
        "COPERNICUS Trial",
        "ACC/AHA Guidelines"
      ]
    },
    {
      "id": "CV-POST-MI-TRANSITION-008",
      "ta": "Cardiovascular",
      "topic": "Post-MI Discharge GDMT",
      "text": "Post-MI patients with reduced EF should receive GDMT before discharge, including ARNI (if EF ≤40%), beta-blockers, SGLT2i, and statins. Early initiation (within 48-72 hours) improves adherence and outcomes.",
      "cites": [
        "ACC/AHA STEMI Guidelines",
        "ESC Acute MI Guidelines"
      ]
    },
    {
      "id": "CV-TITRATION-CALENDAR-009",
      "ta": "Cardiovascular",
      "topic": "GDMT Titration Protocols",
      "text": "Structured titration protocols with defined follow-up intervals (2-4 weeks) optimize GDMT dosing. Nurse-led HF clinics and remote monitoring support safe up-titration while managing hypotension, bradycardia, and renal function.",
      "cites": [
        "ACC/AHA HF Performance Measures",
        "HF Society Clinical Practice"
      ]
    },
    {
      "id": "CV-READMISSION-PREVENTION-010",
      "ta": "Cardiovascular",
      "topic": "HF Readmission Reduction Strategies",
      "text": "Transitional care interventions (7-day follow-up, medication reconciliation, patient education, telemonitoring) reduce 30-day HF readmissions. Pharmacy support for copay assistance and prior authorization streamlines GDMT access.",
      "cites": [
        "ACC/AHA Quality Measures",
        "CMS Hospital Readmissions Reduction Program"
      ]
    },
    {
      "id": "COVID-PAXLOVID-INDICATIONS-001",
      "ta": "COVID-19",
      "topic": "Paxlovid Indications and Efficacy",
      "text": "Nirmatrelvir/ritonavir (Paxlovid) is authorized for treatment of mild-to-moderate COVID-19 in high-risk adults and pediatric patients (≥12 years, ≥40 kg) within 5 days of symptom onset, reducing hospitalization/death by ~89% when started early.",
      "cites": [
        "FDA EUA - Paxlovid",
        "EPIC-HR Trial",
        "NIH COVID-19 Treatment Guidelines"
      ]
    },
    {
      "id": "COVID-PAXLOVID-DDI-002",
      "ta": "COVID-19",
      "topic": "Paxlovid Drug-Drug Interactions",
      "text": "Ritonavir is a strong CYP3A4 inhibitor, causing significant drug-drug interactions with statins, immunosuppressants, anticoagulants, and calcium channel blockers. Review medication list and consider dose adjustments or temporary holds during 5-day course.",
      "cites": [
        "FDA EUA - Paxlovid DDI Table",
        "Liverpool COVID-19 Drug Interactions Checker"
      ]
    },
    {
      "id": "COVID-PAXLOVID-REBOUND-003",
      "ta": "COVID-19",
      "topic": "COVID-19 Rebound Phenomenon",
      "text": "Viral and symptom rebound (2-8 days post-treatment) occurs in ~5-10% of Paxlovid-treated patients. Patients should be counseled to isolate if symptoms return and seek re-evaluation; no evidence supports extended or repeat courses.",
      "cites": [
        "CDC COVID-19 Clinical Guidance",
        "NIH Treatment Guidelines"
      ]
    },
    {
      "id": "COVID-REMDESIVIR-OUTPATIENT-004",
      "ta": "COVID-19",
      "topic": "Remdesivir Outpatient Infusion",
      "text": "Remdesivir 3-day IV course (200 mg day 1, 100 mg days 2-3) is authorized for non-hospitalized high-risk COVID-19 patients within 7 days of symptom onset, reducing hospitalization by 87% in PINETREE trial. Requires infusion capacity.",
      "cites": [
        "FDA EUA - Remdesivir",
        "PINETREE Trial",
        "NIH Guidelines"
      ]
    },
    {
      "id": "COVID-HIGH-RISK-CRITERIA-005",
      "ta": "COVID-19",
      "topic": "High-Risk Patient Criteria",
      "text": "High-risk criteria for severe COVID-19 include age ≥65, immunosuppression, obesity (BMI ≥35), chronic lung disease, diabetes, cardiovascular disease, chronic kidney disease, and pregnancy. These patients benefit most from early antiviral treatment.",
      "cites": [
        "NIH COVID-19 Treatment Guidelines",
        "CDC High-Risk Populations"
      ]
    },
    {
      "id": "COVID-MOLNUPIRAVIR-006",
      "ta": "COVID-19",
      "topic": "Molnupiravir Alternative Therapy",
      "text": "Molnupiravir is authorized for high-risk adults when Paxlovid and remdesivir are not accessible or clinically appropriate. Efficacy (30% hospitalization reduction) is lower than Paxlovid; avoid in pregnancy due to genotoxicity concerns.",
      "cites": [
        "FDA EUA - Molnupiravir",
        "MOVe-OUT Trial",
        "NIH Guidelines"
      ]
    },
    {
      "id": "COVID-INITIATION-TIMING-007",
      "ta": "COVID-19",
      "topic": "Early Treatment Initiation",
      "text": "Antiviral efficacy decreases significantly after 5 days of symptoms. Clinical workflows should enable same-day or next-day evaluation, testing, and treatment initiation for high-risk patients to maximize benefit.",
      "cites": [
        "NIH Treatment Guidelines",
        "CDC Clinical Guidance"
      ]
    },
    {
      "id": "COVID-HOME-INFUSION-008",
      "ta": "COVID-19",
      "topic": "Hospital-at-Home and Infusion Access",
      "text": "Home infusion services enable remdesivir administration for patients with transport barriers or post-discharge needs. Coordination with home health vendors and discharge planning optimizes access and reduces readmissions.",
      "cites": [
        "CMS Hospital-at-Home Waiver Guidance",
        "Infusion Nursing Standards"
      ]
    },
    {
      "id": "COVID-IMMUNOCOMPROMISED-009",
      "ta": "COVID-19",
      "topic": "Immunocompromised Patient Considerations",
      "text": "Immunocompromised patients (transplant, chemotherapy, HIV with low CD4) may have prolonged viral replication and benefit from extended antiviral courses. Infectious disease consultation is recommended for complex cases.",
      "cites": [
        "NIH Guidelines - Special Populations",
        "IDSA COVID-19 Treatment Guidelines"
      ]
    },
    {
      "id": "COVID-MONOCLONAL-ANTIBODIES-010",
      "ta": "COVID-19",
      "topic": "Monoclonal Antibody Considerations",
      "text": "Bebtelovimab and other monoclonal antibodies have limited activity against current Omicron subvariants. Verify current CDC and NIH guidance on authorized mAbs based on regional variant surveillance before prescribing.",
      "cites": [
        "NIH COVID-19 Treatment Guidelines",
        "CDC Variant Surveillance"
      ]
    },
    {
      "id": "VAC-FLU-RECOMMENDATIONS-001",
      "ta": "Vaccines",
      "topic": "Annual Influenza Vaccination",
      "text": "Annual influenza vaccination is recommended for all persons ≥6 months of age. Inactivated influenza vaccine (IIV) and recombinant influenza vaccine (RIV) are preferred over live attenuated vaccine (LAIV) for most populations.",
      "cites": [
        "CDC ACIP Influenza Recommendations 2024-2025",
        "MMWR"
      ]
    },
    {
      "id": "VAC-FLU-HIGH-DOSE-002",
      "ta": "Vaccines",
      "topic": "Enhanced Flu Vaccines for Older Adults",
      "text": "Adults ≥65 years should receive high-dose inactivated (Fluzone High-Dose), recombinant (Flublok), or adjuvanted (Fluad) influenza vaccines, which provide superior immunogenicity and efficacy compared to standard-dose vaccines.",
      "cites": [
        "CDC ACIP Recommendations",
        "FDA Approvals - Enhanced Flu Vaccines"
      ]
    },
    {
      "id": "VAC-FLU-TIMING-003",
      "ta": "Vaccines",
      "topic": "Optimal Timing for Flu Vaccination",
      "text": "Influenza vaccination should ideally occur by end of October, but vaccination throughout the influenza season (into January or later) is beneficial. Early vaccination (July-August) may result in waning immunity before season peak.",
      "cites": [
        "CDC ACIP Influenza Recommendations",
        "MMWR"
      ]
    },
    {
      "id": "VAC-PNEUMOCOCCAL-ADULTS-004",
      "ta": "Vaccines",
      "topic": "Pneumococcal Vaccination for Adults",
      "text": "Adults ≥65 years should receive pneumococcal vaccination with PCV15 or PCV20. If PCV15 is used, follow with PPSV23 ≥1 year later. Adults 19-64 with chronic conditions or immunocompromising conditions also require pneumococcal vaccination.",
      "cites": [
        "CDC ACIP Pneumococcal Recommendations",
        "MMWR 2022"
      ]
    },
    {
      "id": "VAC-RSV-OLDER-ADULTS-005",
      "ta": "Vaccines",
      "topic": "RSV Vaccination for Older Adults",
      "text": "A single dose of RSV vaccine (RSVPreF3 or RSVpreF) is recommended for adults ≥60 years using shared clinical decision-making, particularly for those with chronic cardiopulmonary disease or residing in long-term care facilities.",
      "cites": [
        "CDC ACIP RSV Recommendations 2023",
        "FDA Approvals - RSV Vaccines"
      ]
    },
    {
      "id": "VAC-SHINGLES-SHINGRIX-006",
      "ta": "Vaccines",
      "topic": "Shingles Vaccination (Shingrix)",
      "text": "Recombinant zoster vaccine (RZV, Shingrix) is recommended for adults ≥50 years as a 2-dose series (0, 2-6 months), providing >90% efficacy against shingles and postherpetic neuralgia. Preferred over live zoster vaccine (ZVL).",
      "cites": [
        "CDC ACIP Herpes Zoster Recommendations",
        "Shingrix Efficacy Trials"
      ]
    },
    {
      "id": "VAC-VIS-DOCUMENTATION-007",
      "ta": "Vaccines",
      "topic": "Vaccine Information Statements (VIS)",
      "text": "Federal law requires providing current VIS documents before administering ACIP-recommended vaccines and documenting VIS edition date, vaccine administration date, manufacturer, lot number, and administrator in the patient record.",
      "cites": [
        "CDC VIS Requirements",
        "National Childhood Vaccine Injury Act"
      ]
    },
    {
      "id": "VAC-STANDING-ORDERS-008",
      "ta": "Vaccines",
      "topic": "Standing Orders for Vaccination",
      "text": "Standing orders allow nurses and pharmacists to assess and vaccinate patients without individual physician orders, increasing vaccination rates. Protocols must comply with state scope-of-practice laws and include contraindication screening.",
      "cites": [
        "CDC Standing Orders Best Practices",
        "AMA Policy on Standing Orders"
      ]
    },
    {
      "id": "VAC-IMMUNOCOMPROMISED-009",
      "ta": "Vaccines",
      "topic": "Vaccination in Immunocompromised Patients",
      "text": "Immunocompromised patients (transplant, HIV, chemotherapy, immunosuppressive therapy) should receive inactivated vaccines per accelerated schedules and higher doses where indicated (e.g., double-dose hepatitis B). Live vaccines are generally contraindicated.",
      "cites": [
        "CDC ACIP Immunocompromised Recommendations",
        "IDSA Vaccination Guidelines"
      ]
    },
    {
      "id": "VAC-RECALL-SYSTEMS-010",
      "ta": "Vaccines",
      "topic": "Reminder-Recall Systems",
      "text": "EHR-integrated reminder-recall systems using SMS, phone calls, or patient portals improve vaccination coverage. Automated reminders 1-2 weeks before due dates and missed-dose outreach increase completion rates for multi-dose series.",
      "cites": [
        "CDC Community Guide - Vaccination",
        "AHRQ Health IT Tools"
      ]
    },
    {
      "id": "DIABETES-MGMT-001",
      "ta": "Diabetes",
      "topic": "Diabetes Management",
      "text": "Effective diabetes management requires a comprehensive approach including lifestyle modifications, glycemic control, cardiovascular risk reduction, and regular monitoring. Key strategies include healthy eating, physical activity, medication adherence, and routine check-ups.",
      "cites": [
        "ADA Standards of Care 2024",
        "AHA/ACC Diabetes Guidelines"
      ]
    }
  ]
}
